A rare B cell clonotype imprinted by ancestral SARS-CoV-2 develops cross-sarbecovirus neutralization in immune recalls.

Publication date: Jul 04, 2025

The ultimate potential of B cells imprinted by ancestral SARS-CoV-2 in developing neutralizing breadth and potency remains to be explored. Here, we longitudinally tracked B cells that recognize the wild-type spike in two individuals who were repeatedly infected by Omicron variants after receiving prototype mRNA vaccines. Functional and genetic analysis of 632 monoclonal antibodies (mAbs) from those B cells reveals that mAbs cloned after a second infection have dramatically enhanced neutralizing breadth and potency due to immune recalls. Among the eleven mAbs that broadly neutralize SARS-CoV-2 variants from the wild type to KP. 3, five mAbs are classified into public clonotypes encoded by IGHV3-53 or IGHV3-66, whereas the rest belong to a rare clonotype encoded by IGHV3-74. Notably, IGHV3-74 mAbs can also potently neutralize other sarbecoviruses by targeting a non-dominant epitope partially overlapping with receptor-binding domain (RBD)-3 and RBD-5. These results support that ancestral SARS-CoV-2 immune imprinting can be harnessed in developing pan-SARS-CoV-2 and even cross-sarbecovirus vaccines.

Open Access PDF

Concepts Keywords
Genetic CP: Immunology
Potency cross-sarbecovirus neutralization
Sarbecoviruses epitope mapping
Spike IGHV3-53/3-66
IGHV3-74
immune imprinting
pan-SARS-CoV-2 neutralization
repeated Omicron infection
SARS-CoV-2

Semantics

Type Source Name
disease IDO cell
disease MESH infection
disease IDO intervention
pathway REACTOME Metabolism
pathway REACTOME Adaptive Immune System
disease IDO process
drug DRUGBANK Methylergometrine
disease IDO blood
disease MESH SARS CoV 2 infection
drug DRUGBANK Hexocyclium
disease MESH breakthrough infection
disease MESH reinfection
disease MESH asymptomatic infection
disease IDO assay
drug DRUGBANK Proline
drug DRUGBANK Esomeprazole
drug DRUGBANK Hyaluronic acid
disease MESH convalescence
disease IDO history
drug DRUGBANK Trestolone
drug DRUGBANK Guanosine
disease IDO host
drug DRUGBANK Inosine
drug DRUGBANK Efavirenz
disease IDO reagent
drug DRUGBANK Immune Globulin Human
drug DRUGBANK Streptomycin
drug DRUGBANK Flunarizine
drug DRUGBANK Coenzyme M
drug DRUGBANK Sodium lauryl sulfate
drug DRUGBANK Gold
drug DRUGBANK Titanium

Original Article

(Visited 1 times, 1 visits today)